SLC5A2 and diabetic kidney disease: However, differing from Zou et al., our analysis shows that ‘SGLT2 inhibitors’, ‘GLP-1Ras’, and anti-inflammatory agents are the emerging trends of DKD and reveals an insufficiency of high-quality researches on the prediction and biomarker of DKD.